There are 36 resources available
Patient’s advocate point of view
Presenter: K. Kastrati, DE
Session: SESSION 4 - Debate around adjuvant therapy for Bladder and RCC
Resources:
Slides
Webcast
Treatment after progression on adjuvant therapy in renal and bladder cancer
Presenter: U. Vogl, CH
Session: SESSION 4 - Debate around adjuvant therapy for Bladder and RCC
Resources:
Slides
Webcast
Participants clinical case discussion: Metastasectomy in renal cancer treated with immunotherapy
Presenter: E. Bagiokou, GR
Session: SESSION 4 - Debate around adjuvant therapy for Bladder and RCC
Resources:
Slides
Webcast
Participants clinical case discussion: A hole in one with pembrolizumab
Presenter: M. Bienz, UK
Session: SESSION 4 - Debate around adjuvant therapy for Bladder and RCC
Resources:
Slides
Webcast
Participants clinical case discussion: Neoadjuvant treatment for small-cell cancer of the bladder and late paraneoplastic problems
Presenter: A.M. Schmitt, CH
Session: SESSION 4 - Debate around adjuvant therapy for Bladder and RCC
Resources:
Slides
Webcast
Debate: Immune combinations or VEGF/PD1 inhibition as 1st line therapy for advanced clear cell RCC - Immune combinations
Presenter: L. Albiges, FR
Session: SESSION 5 - Renal Cancer – Part II
Resources:
Slides
Webcast
Debate: Immune combinations or VEGF/PD1 inhibition as 1st line therapy for advanced clear cell RCC - VEGF/PD1 inhibition
Presenter: V. Grünwald, DE
Session: SESSION 5 - Renal Cancer – Part II
Resources:
Slides
Webcast
Individualized therapy in frontline and beyond
Presenter: L. Albiges, FR
Session: SESSION 5 - Renal Cancer – Part II
Resources:
Slides
Webcast
Biology and treatment of non-clear RCC
Presenter: B. Szabados, UK
Session: SESSION 5 - Renal Cancer – Part II
Resources:
Slides
Webcast
Can we stop targeted therapy, immune therapy?
Presenter: V. Grünwald, DE
Session: SESSION 6 - Focus on toxicity and duration of therapy
Resources:
Slides
Webcast